Abstract:
In their study, McKinney et al. showed the high potential of artificial intelligence for breast cancer screening. However, the lack of detailed methods and computer code undermines its scientific value. We identify obstacles hindering transparent and reproducible AI research as faced by McKinney et al and provide solutions with implications for the broader field.
Main Text:
The evaluation of deep learning for the detection of breast cancer from mammograms by McKinney and colleagues 1 showed promising improvements in screening performance, while highlighting challenges around the reproducibility and transparency of artificial intelligence ( AI) research. They assert that their system improves the speed and robustness of breast cancer screening, generalizes to populations beyond those used for training, and outperforms radiologists in specific settings. Upon successful prospective validation, this new system holds great potential for streamlining clinical workflows, reducing false positives, and improving patient outcomes. However, the absence of sufficiently documented methods and computer code underlying the study effectively undermines its scientific value. This shortcoming limits the evidence required for others to prospectively validate and clinically implement such technologies. Here, we identify obstacles hindering transparent and reproducible AI research as faced by McKinney et al. and provide potential solutions with implications for the broader field.
Scientific progress depends upon the ability of independent researchers to (1) scrutinize the results of a research study, (2) reproduce the study's main results using its materials, and (3) build upon them in future studies 2 . Publication of insufficiently documented research violates the core principles underlying scientific discovery 3, 4 . The authors state " The code used for training the models has a large number of dependencies on internal tooling, infrastructure and hardware, and its release is therefore not feasible" . Computational reproducibility is indispensable for robust AI applications 5,6 more complex methods demand greater transparency 7 . In the absence of code, reproducibility falls back on replicating methods from textual description. Although, the authors claim that "all experiments and implementation details are described in sufficient detail in the Supplementary Methods section to support replication with non-proprietary libraries" , key details about their analysis are lacking. Even with sufficient description, reproducing complex computational pipelines based purely on text is a subjective and challenging task 8,9 . More specifically, the authors' description of the model development as well as data processing and training pipelines lacks critical details. The definition of multiple hyperparameters for the model's architecture (composed of three networks referred to as the Breast, Lesion, and Case models) is missing ( Table 1 ). The authors did not disclose the parameters used for data augmentation; the transformations used are stochastic and can significantly affect model performance 10 . Details of the training pipeline were also missing. For instance, they state that the mini-batches were sampled to contain an equal proportion of negative and positive examples, potentially leading to multiple instances of the same patients in a given epoch. Deep learning optimization algorithms such as stochastic gradient descent typically operate under the assumption that a given sample is provided to the model exactly once per epoch. The lack of detail regarding the per-batch balancing of classes prevents replicating the training pipeline.
There exist numerous frameworks and platforms to make artificial intelligence research more transparent and reproducible ( Table 2) Another crucial aspect of ensuring reproducibility lies in access to the data the models were derived from. In their study, McKinney et al. used two large datasets under license, properly disclosing this limitation in their publication. Sharing of patient health information is highly regulated due to privacy concerns. Despite these challenges, sharing of raw data has become more common in biomedical literature, increasing from under 1% in the early 2000s to 20% today 11 . However, if the data cannot be shared, the model predictions and data labels themselves should be released, allowing further statistical analyses.
Although sharing of code and data is widely seen as a crucial part of scientific research, the adoption varies across fields. In fields such as genomics, complex computational pipelines and sensitive datasets have been shared for decades 12 . Guidelines related to genomic data are clear, detailed, and most importantly, enforced. It is generally accepted that all code and data are released alongside a publication. In other fields of medicine and science as a whole, this is much less common, and data and code are rarely made available. For scientific efforts where a clinical application is envisioned and human lives would be at stake, we argue that the bar of transparency should be set even higher. If data cannot be shared with the entire scientific community, because of licensing or other insurmountable issues, at a minimum a mechanism should be set so that some highly-trained, independent investigators can access the data and verify the analyses. This would allow a truly adequate peer-review of the study and its evidence before moving into clinical implementation.
Many egregious failures of science were due to lack of public access to code and data used in the discovery process 13, 14 . These unfortunate lessons should not be lost on either journal editors or its readers. Journals have an obligation to hold authors to the standards of reproducibility that benefit not only other researchers, but also the creators of a given method. Making one's methods reproducible may surface biases or shortcomings to authors before publication 15 . Preventing external validation of a model will likely reduce its impact and could lead to unintended consequences 15 We have high hopes for the utility of AI methods in medicine. Ensuring that these methods meet their potential, however, requires that these studies be reproducible. Unfortunately, the biomedical literature is littered with studies that have failed the test of reproducibility, and many of these can be tied to methodologies and experimental practices that could not be investigated due to failure to fully disclose software and data. This is even more important for applications intended for use in the diagnosis or treatment of human disease. 
